BeOne Medicines (BEIGF) Cash & Equivalents (2015 - 2026)

BeOne Medicines (BEIGF) has reported Cash & Equivalents for 12 consecutive years, with $5.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 84.98% year-over-year to $5.1 billion in Q2 2026; TTM through Jun 2026 was $5.1 billion, a 84.98% increase from a year earlier, with the FY2025 full-year figure at $4.5 billion, up 73.08% from the prior year.
• Cash & Equivalents was $5.1 billion for Q2 2026 at BeOne Medicines, up from $4.8 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $5.1 billion in Q2 2026 and troughed at $2.5 billion in Q1 2025.
• A 5-year average of $3.6 billion and a median of $3.5 billion in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 203.41% in 2022 and dropped 26.92% in 2023, its largest moves.
• Over 5 years, Cash & Equivalents stood at $3.9 billion in 2022, then slipped by 18.03% to $3.2 billion in 2023, then dropped by 17.16% to $2.6 billion in 2024, then soared by 73.08% to $4.5 billion in 2025, then increased by 12.11% to $5.1 billion in 2026.
• The last three Cash & Equivalents figures came in at $5.1 billion (Q2 2026), $4.8 billion (Q1 2026), and $4.5 billion (Q4 2025), per Business Quant data.